Abacavir / Lamivudine / Zidovudine
Abacavir/Lamivudine/Zidovudine is a triple-nucleoside reverse transcriptase inhibitor (NRTI) combination used to treat HIV-1 infection. This fixed-dose combination works by inhibiting the reverse transcriptase enzyme, preventing viral replication and reducing HIV viral load. It is typically prescribed as part of a comprehensive antiretroviral regimen for patients with HIV/AIDS.
A three-drug antiretroviral combination used to manage HIV infection by inhibiting viral replication.
Key facts at a glance
- RxNorm
- 284620
- Generic
- Abacavir / Lamivudine / Zidovudine
- Class
- multi-ingredient
- Brands
- Trizivir
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 1 tablet (300mg/150mg/300mg) twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 1 tablet twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 1 tablet once daily or twice daily based on renal function
- Maximum
- consult physician
- Frequency
- once daily or every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
first trimesteruse only if benefits outweigh risks
consider alternative regimens; if used, continue throughout pregnancy to prevent vertical transmission
regular fetal monitoring, viral load monitoring
Use with caution and monitor for adverse effects.
pregnancy
third trimestercontinue therapy
antiretroviral therapy should be continued to reduce HIV transmission risk
viral load monitoring, CD4 count, hematologic monitoring
Use with caution and monitor for adverse effects.
lactation
breastfeedingavoid breastfeeding
HIV-positive mothers should not breastfeed regardless of therapy to prevent transmission
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderlyno specific dose adjustment
use with caution due to increased susceptibility to adverse effects
regular monitoring of renal function, hematologic parameters
Use with caution and monitor for adverse effects.
pediatric_age
children under 12not recommended
fixed-dose combination not appropriate for pediatric dosing requirements
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
severe renal impairmentavoid use
zidovudine and lamivudine require dose adjustment in renal impairment; fixed-dose combination cannot be dose-adjusted
not applicable
Use of this medication in this population requires careful consideration of risks and benefits.
hepatic_impairment
moderate to severeavoid use
abacavir and zidovudine require dose adjustment in hepatic impairment
liver function monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
alcohol_users
chronic alcohol useavoid concurrent use
alcohol increases risk of abacavir-associated lactic acidosis and hepatotoxicity
liver function tests, lactate levels
Use of this medication in this population requires careful consideration of risks and benefits.
Statistics and clinical data
FDA approval year
Trizivir approval date by FDA
Drug class
Pharmacological classification of the fixed-dose combination
Common uses
Primary therapeutic indication for the combination drug
Standard adult dose
Recommended dosing regimen for adult patients
Treatment of HIV-1 infection in adults and children weighing at least 40 kg, typically as part of combination antiretroviral therapy.
Each component is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV reverse transcriptase enzyme, preventing viral RNA from being converted to DNA, thereby inhibiting viral replication.
Carries boxed warnings for hypersensitivity reactions (particularly abacavir-related, especially in HLA-B*5701 positive patients) and lactic acidosis/hepatomegaly. Zidovudine component may cause bone marrow suppression and anemia. Requires HLA-B*5701 testing before initiating therapy. Not recommended for patients with hepatic impairment.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 24, 2026. · Read our editorial policy